-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GravisMuSK
- Pathogenesis of MuSK antibody-positive MG:
- Clinical features of MuSK-MG myasthenia gravis:
How to treat myasthenia gravis? There was no significant difference in the treatment response of patients with MuSK and AChR subtypes in the combined immunopharmaceutical therapy
.
Both MuSK and AChR-typed patients showed better improvement with PLEX than IVIG during MC
.
4.
How to distinguish MuSK-MG patients?
Reference:
Clinical characteristics of patients with MuSK antibody-positive myasthenia gravis in South China--Author: Lu Yaru Ou Changyi et al.
Detection of different antibodies in myasthenia gravis and its clinical significance--Author: Li Yuan, Chu Lan, et al
Myasthenia gravis-related autoantibodies and their clinical significance Advances in Detection Methods -- Author: Huang Xinxin, Zhu Desheng, etc.